How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis [0.03%]
唾液用于抗病毒治疗药物监测的可行性如何？系统评价和分析
Cassandra Weng-Yan Lai,Suzanne A M Wenker,Paul W Groundwater et al.
Cassandra Weng-Yan Lai et al.
Background and objective: Immunosuppressed patients are susceptible to serious viral infections, often necessitating antiviral prophylaxis and/or treatment. Therapeutic drug monitoring (TDM) has been proposed to optimise ...
Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma [0.03%]
基于Epcoritamab单药治疗复发/难治性滤泡淋巴瘤的剂量反应关系指导其给药方案优化的研究
Mahipal Sinnollareddy,Kinjal Sanghavi,Leonid Gibiansky et al.
Mahipal Sinnollareddy et al.
Background: Epcoritamab is approved for treating various relapsed/refractory (R/R) lymphomas. In a phase I/II study in R/R follicular lymphoma (FL) patients, epcoritamab demonstrated high response rates (EPCORE NHL-1: obj...
Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir/Emtricitabine/Tenofovir Alafenamide Fumarate [0.03%]
基于模拟预测支持达芦那韦/埃特拉韦固定剂量复合剂的研发
Hylke Waalewijn,Lisanne A H Bevers,Linda L Lewis et al.
Hylke Waalewijn et al.
Background and objective: Approximately 1.4 million children (aged 0-14 years) are living with human immunodeficiency virus, most infected through mother-to-child transmission. Despite the availability of combination anti...
Correction: Population Pharmacokinetic Analysis of Enalapril and Enalaprilat in Newly Treated Children with Heart Failure: Implications for Safe Dosing of Enalapril (LENA Studies) [0.03%]
伦纳研究：厄贝沙坦治疗新诊断的心力衰竭儿童的群体药代动力学分析及安全用药建议纠正声明
Melina Steichert,Willi Cawello,Stephanie Laeer;LENA Consortium
Melina Steichert
Published Erratum
Clinical pharmacokinetics. 2026 Jul 29. DOI:10.1007/s40262-026-01677-7 2026
Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation [0.03%]
基于I期剂量寻找试验（ITCC-054/COG AAML1921）和儿科II期推荐剂量评估的费城染色体阳性慢性粒细胞白血病儿童波舒替尼药物代谢动力学研究
Jen-Hao Wu,Francisco Bautista,Erica Brivio et al.
Jen-Hao Wu et al.
Background and objectives: Bosutinib, an orally administered dual Src and Bcr-Abl tyrosine kinase inhibitor (TKI), is approved for the treatment of chronic phase Philadelphia chromosome-positive chronic myelogenous leukem...
Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease [0.03%]
vedolizumab在健康成人和炎症性肠病患者中的生理药动学模型分析
Sanjana Parikh,Kei Irie,Ryota Tanaka et al.
Sanjana Parikh et al.
Background and objective: Vedolizumab is a gut-selective, humanized monoclonal antibody that binds to α4β7 integrin, preventing lymphocyte trafficking to the intestinal mucosa. While approved for adults with moderate-to...
The Effect of Food and the Proton Pump Inhibitor Rabeprazole on Binimetinib Pharmacokinetics in Healthy Participants [0.03%]
在健康受试者中，食物和II型磷酸二酯酶抑制剂兰索拉唑对_binimetinib_药动学的影响研究
Erik Hahn,Joseph Piscitelli,Dustin Huynh et al.
Erik Hahn et al.
Background: Binimetinib is a selective and potent MEK1/MEK2 inhibitor approved in combination with encorafenib for patients with BRAF-mutant melanoma and non-small cell lung cancer. Binimetinib is a basic amine with pH-de...
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn's Disease [0.03%]
抗TNF诱导期间的药代动力学目标及其与儿童克罗恩病深度缓解的相关性
Alexander Nasr,Tomoyuki Mizuno,Kei Irie et al.
Alexander Nasr et al.
Background and objective: Personalizing anti-tumor necrosis factor (TNF) therapy in pediatric Crohn's disease (CD) remains challenging due to variable drug clearance and response. Identifying pharmacokinetic (PK) and phar...
Low Tacrolimus C0/Dose Ratio is Associated with Higher Cmax and AUC Despite Similar Pre-dose Concentrations [0.03%]
低他克莫司C0/dosage比率与较高的Cmax和AUC有关，尽管相似的给药浓度
Amar D Levens,Teun van Gelder,Armin Gelinck et al.
Amar D Levens et al.
Background and objective: Tacrolimus therapeutic drug monitoring after kidney transplantation is primarily guided by the pre-dose concentration (C0), assuming it reflects overall drug exposure. At the same time, the tacro...
A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics [0.03%]
评估CYP3A5基因型及其他临床协变量对他克莫司药代动力学影响的群体药代动力学模型和给药算法综述
Riley M Randolph,Sara Jubas,Li Gong et al.
Riley M Randolph et al.
Tacrolimus is a narrow therapeutic index drug with wide intrapatient and interpatient pharmacokinetic variability and cytochrome P450 3A5 (CYP3A5) genotype-guided dosing recommendations. This review aimed to evaluate population pharmacokine...